First presentation of clinical trial data examining the immune response in women aged 26-55 demonstrate 100 per cent vaccine-induced antibody response against HPV 16/18. MISSISSAUGA, ON, June 5 /CNW/ - The first data to be presented from a clinical trial examining the immune response in women aged 26-55, demonstrated that GlaxoSmithKline's (NYSE and LSE: GSK - News News) cervical cancer candidate vaccine is highly immunogenic and well-tolerated. The data, presented today at the 2006 American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, GA.(Abstract No: 1008), add to the growing body of evidence supporting the vaccine's ability to provide strong and sustained immune response in women of all ages.
